Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in PTC Therapeutics, Inc., Arrowhead Pharmaceuticals or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how PTC Therapeutics, Inc., Arrowhead Pharmaceuticals and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About PTC Therapeutics, Inc., Arrowhead Pharmaceuticals and Inc.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich’s ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Latest Biotechnology and PTC Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc. Stock News

As of July 30, 2026, PTC Therapeutics, Inc. had a $6.3 billion market capitalization, compared to the Biotechnology median of $251.9 million. PTC Therapeutics, Inc.’s stock is down 10.8% in 2026, down 11.8% in the previous five trading days and up 53.22% in the past year.

Currently, PTC Therapeutics, Inc. does not have a price-earnings ratio. PTC Therapeutics, Inc.’s trailing 12-month revenue is $827.1 million with a -22.6% net profit margin. Year-over-year quarterly sales growth most recently was -76.8%. Analysts expect adjusted earnings to reach $1.320 per share for the current fiscal year. PTC Therapeutics, Inc. does not currently pay a dividend.

As of July 30, 2026, Arrowhead Pharmaceuticals, Inc. had a $12.3 billion market cap, putting it in the 80th percentile of all stocks. Arrowhead Pharmaceuticals, Inc.’s stock is up 28.1% in 2026, down 0.7% in the previous five trading days and up 448.49% in the past year.

Currently, Arrowhead Pharmaceuticals, Inc. does not have a price-earnings ratio. Arrowhead Pharmaceuticals, Inc.’s trailing 12-month revenue is $622.0 million with a -48.4% net profit margin. Year-over-year quarterly sales growth most recently was -86.4%. Analysts expect adjusted earnings to reach $-3.083 per share for the current fiscal year. Arrowhead Pharmaceuticals, Inc. does not currently pay a dividend.

How We Compare PTC Therapeutics, Inc., Arrowhead Pharmaceuticals and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at PTC Therapeutics, Inc., Arrowhead Pharmaceuticals and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

PTC Therapeutics, Inc., Arrowhead Pharmaceuticals and Inc. Stock Value Grades

Company	Ticker	Value
PTC Therapeutics, Inc.	PTCT	na
Arrowhead Pharmaceuticals, Inc.	ARWR	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

PTC Therapeutics, Inc. does not have a meaningful Value Score. Arrowhead Pharmaceuticals, Inc. has a Value Score of 3, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither PTC Therapeutics, Inc., Arrowhead Pharmaceuticals or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if PTC Therapeutics, Inc., Arrowhead Pharmaceuticals or Inc. is the better investment when it comes to value.

PTC Therapeutics, Inc., Arrowhead Pharmaceuticals and Inc.’s Quality Grades

Company	Ticker	Quality
PTC Therapeutics, Inc.	PTCT	F
Arrowhead Pharmaceuticals, Inc.	ARWR	D

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

PTC Therapeutics, Inc. has a Quality Score of 8, which is Very Weak. Arrowhead Pharmaceuticals, Inc. has a Quality Score of 27, which is Weak.

The Quality Stock Winner: No Clear Winner

Neither PTC Therapeutics, Inc., Arrowhead Pharmaceuticals or Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if PTC Therapeutics, Inc., Arrowhead Pharmaceuticals or Inc. is the better investment when it comes to quality.

PTC Therapeutics, Inc., Arrowhead Pharmaceuticals and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
PTC Therapeutics, Inc.	PTCT	C
Arrowhead Pharmaceuticals, Inc.	ARWR	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

PTC Therapeutics, Inc. has a Earnings Estimate Score of 55, which is Neutral. Arrowhead Pharmaceuticals, Inc. has a Earnings Estimate Score of 43, which is Neutral.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither PTC Therapeutics, Inc., Arrowhead Pharmaceuticals or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if PTC Therapeutics, Inc., Arrowhead Pharmaceuticals or Inc. is the better investment when it comes to estimate revisions.

Other PTC Therapeutics, Inc., Arrowhead Pharmaceuticals and Inc. Grades

In addition to Value, Quality and Estimate Revisions, A+ Investor also provides grades for Growth and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether PTC Therapeutics, Inc., Arrowhead Pharmaceuticals and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, PTC Therapeutics, Inc., Arrowhead Pharmaceuticals or Inc. Stock?

Overall, PTC Therapeutics, Inc. stock has a Value Score of , Estimate Revisions Score of 55 and Quality Score of 8.

Arrowhead Pharmaceuticals, Inc. stock has a Value Score of 3, Estimate Revisions Score of 43 and Quality Score of 27.

Comparing PTC Therapeutics, Inc., Arrowhead Pharmaceuticals and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.